FRONTGRADE-GAISLER
The European Space Agency (ESA) has awarded Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space applications, a contract under the ARTES Core Competitiveness programme to qualify the GR716B microcontroller for flight. This state-of-the-art microcontroller is specifically designed for spacecraft avionics, and its prototype is expected to be released later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627644895/en/
The European Space Agency (ESA) has awarded Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space applications, a contract under the ARTES Core Competitiveness programme to qualify the GR716B microcontroller for flight. This state-of-the-art microcontroller is specifically designed for spacecraft avionics, and its prototype is expected to be released later this year. (Photo: Business Wire)
The ESA contract will support the rigorous flight qualification process for the GR716B, ensuring that it meets the highest standards for reliability of critical space missions. Flight qualification will verify that the microcontroller can operate reliably while encountering the harsh conditions of space.
“We are thrilled to receive this significant contract from ESA,” said Sandi Habinc, General Manager of Frontgrade Gaisler. “The GR716B microcontroller represents a major advancement in our technology, offering enhanced analogue functionalities for space missions. This contract not only validates our efforts but also accelerates the availability of this technology to the space industry.”
The many interfaces that GR716B offers allow it to support a wide variety of applications and serve as an integral part of any spacecraft subsystem, ranging from ensuring stable power delivery to controlling motors and magnetorquers. This versatility makes it ideal for advanced space missions requiring robust and reliable performance.
“We are very pleased to support the development of the GR716B through our ARTES Core Competitiveness programme,” said Domenico Mignolo, Acting Head of Technology and Products Division in ESA’s Connectivity and Secure Communications (CSC) Directorate. “The GR716B is an innovative product that will allow improved reliability and flexibility.”
The GR716B microcontroller offers enhanced capabilities over the company’s GR716A microcontroller, with the latest version offering higher performance and a broader range of interfaces while maintaining software compatibility.
Frontgrade Gaisler is also evaluating a GR716B System-in-Package solution, composed of both the microcontroller and non-volatile memory, which would greatly simplify system integration and board design.
About Frontgrade Gaisler
Frontgrade Gaisler is a leading provider of radiation-hardened microprocessors and IP cores for critical applications, particularly in the space industry. The company’s processors are known for their reliability, fault tolerance, and radiation tolerance, making them ideal for any space mission or other high-reliability application.
About ESA’s ARTES Core Competitiveness programme line
ESA’s ARTES Core Competitiveness programme aims to maintain and improve the capability and competitiveness of European and Canadian industry in the satellite communication market. The programme combines two elements, ARTES Advanced Technology and ARTES Competitiveness and Growth, to support technological development from concept to fully-fledged product, system or service.
Learn more at https://connectivity.esa.int/core-competitiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627644895/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom